Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Stock Chart & Stats
$33.40
-$0.34(-3.65%)
At close: 4:00 PM EST
$33.40
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$5.35 - $40.22
Previous CloseN/A
Volume337.58K
Average Volume (3M)778.90K
Market Cap
$1.98B
Enterprise Value$1.89B
Total Cash (Recent Filing)$284.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding59,150,790
10 Day Avg. Volume959,222
30 Day Avg. Volume778,896
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue10.26
Enterprise Value/Gross Profit10.37
Enterprise Value/Ebitda-133.63
Forecast
1Y Price Target
$45.25Price Target Upside35.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$26.96M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence StrengthOpen‑label extension results show sustained, clinically meaningful improvements in communication and behavior and propensity‑score adjusted analyses indicate substantially greater seizure reduction versus natural history, reinforcing the treatment's therapeutic value.
Pipeline DiversificationDosing of the first patient in a Phase 1 study of STK‑002 and initiation of a second TANGO‑based program broaden the pipeline and add independent clinical catalysts beyond the lead Dravet program.
Regulatory PathwayU.S. regulators signaled that a reduction in seizure frequency could support approval, creating a clearer and potentially more attainable path to market for zorevunersen.
Bears Say
Approval Timing UncertaintyPursuit of a broader syndrome‑level label and management's requirement for full late‑stage data before broad access could extend the approval timeline and delay commercialization.
Data Robustness ConcernsOpen‑label trial designs and regulators labeling a key efficacy analysis as post‑hoc weaken the strength of the evidence and increase the risk of additional review or requests for more data.
International Pricing RiskInternational pricing rules and potential most‑favored‑nation arrangements could create unpredictability for royalties and revenues outside the United States, pressuring global commercial forecasts.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $5.35 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $1.98B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is May 11, 2026 which is in 47 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Mar 11, 2026. The company reported -$0.992 earnings per share for the quarter, missing the consensus estimate of -$0.931 by -$0.061.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 59,150,790 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.992 in its last earnings report, missing expectations of -$0.931. Following the earnings report the stock price went down -1.069%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.25 (35.48% Upside)
$45.25 (35.48% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $552.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
302.28%
12-Months-Change
Fundamentals
Return on Equity
-2.05%
Trailing 12-Months
Asset Growth
54.09%
Trailing 12-Months
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q3 2025
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$45.25
▲(35.48% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---